NCT06311435

Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 224 (estimated)
• Sponsor: MaxWell Clinic, PLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The Primary objective of this study is to determine, using unblinded samples, if it is possible to develop an algorithm for the classification of specific blood RNA from patients with long COVID together and separately from the apparent health normal controls and other medical conditions that share the signs and symptoms of long COVID.

Detailed description

Participants will be screened and provide two blood samples28 (+/- 2) days apart. Based on the participants survey results they will be placed into one of fourteen groups that reflect the type of Long COVID the patient is experiencing. Samples will be shipped to the sponsor who will develop an AI process to validate the type of Long COVID and assess its severity. The long term goal is to develop a reliable test to identify the presence of Long COVID and its severity.

Conditions

• Long COVID

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	RNA Biomarker Blood Test	Blood will be collected into a PaxGene Blood tube for processing by sponsor

Timeline

• Start date: 2024-03-15
• Primary completion: 2026-03-15
• Completion: 2026-03-15
• First posted: 2024-03-15
• Last updated: 2024-10-18

Locations

3 sites across 1 country: United States